Abstract
AIMS: To compare the serum concentrations of itraconazole and hydroxyitraconazole after treatment with itraconazole cyclodextrin solution and itraconazole capsules in human immunodeficiency virus (HIV) positive patients with oral candidosis. METHODS: The pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole were assessed on days 1 and 7 of therapy in acquired immunodeficiency syndrome (AIDS) patients with oral candidosis taking either itraconazole solution or capsules and the serum concentrations (measured by high performance liquid chromatography) correlated with the clinical response to therapy. In addition, the in vitro susceptibility of Candida spp isolates taken from patients at the start of the therapy was assessed. RESULTS: Nine of 16 patients treated with itraconazole capsules and eight of 15 treated with the solution responded to treatment. Three of the non-responders in each treatment group were infected with isolates resistant to itraconazole in vitro. Although with both preparations there was considerable inter-patient variability in the maximum recorded serum concentrations of itraconazole, they were significantly lower on day 1 and day 7 in those receiving capsules compared with those taking the solution. Patients unresponsive to therapy, but infected with susceptible isolates, had significantly lower concentrations of itraconazole and hydroxyitraconazole levels on days 1 and 7 than patients responding to treatment. However, patients infected with itraconazole resistant isolates (tested in vitro) failed to respond to treatment despite achieving similar serum concentrations of itraconazole and hydroxy-itraconazole to the responsive patients. For patients with in vitro susceptible isolates a serum itraconazole concentration of < 1000 ng/ml on day 7 was predictive of therapeutic failure (specificity 71%, sensitivity 100%). CONCLUSIONS: Itraconazole cyclodextrin solution achieves higher serum itraconazole and hydroxy-itraconazole concentrations than the capsule formulation in AIDS patients, and this is associated with improved efficacy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cartledge J. D., Midgley J., Gazzard B. G. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS. 1997 Feb;11(2):163–168. doi: 10.1097/00002030-199702000-00005. [DOI] [PubMed] [Google Scholar]
- Cartledge J. D., Midgley J., Youle M., Gazzard B. G. Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother. 1994 May;33(5):1071–1073. doi: 10.1093/jac/33.5.1071. [DOI] [PubMed] [Google Scholar]
- Hardin T. C., Graybill J. R., Fetchick R., Woestenborghs R., Rinaldi M. G., Kuhn J. G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988 Sep;32(9):1310–1313. doi: 10.1128/aac.32.9.1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lake-Bakaar G., Tom W., Lake-Bakaar D., Gupta N., Beidas S., Elsakr M., Straus E. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988 Sep 15;109(6):471–473. doi: 10.7326/0003-4819-109-6-471. [DOI] [PubMed] [Google Scholar]
- Odds F. C. Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob Agents Chemother. 1992 Aug;36(8):1727–1737. doi: 10.1128/aac.36.8.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Warnock D. W., Turner A., Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother. 1988 Jan;21(1):93–100. doi: 10.1093/jac/21.1.93. [DOI] [PubMed] [Google Scholar]